# Melanotan 2 References: The Sources Behind This Digest

> Melanotan 2 references: the full, cited source list behind this research digest — Phase I human studies, case reports, and reviews, with PubMed links and DOIs.

Every quantitative claim on this site maps to a numbered source below. Human studies, case reports, and reviews, with PubMed links and DOIs.

## How to read this list

The sources below are numbered to match the inline citations throughout the site. The strongest human evidence is small — Phase I studies of three to twenty subjects for pigmentation and erections. Much of the safety record is built from individual case reports, which establish that a harm can occur but not how often. Reviews and analytical studies round out the picture on regulatory status and product quality. Compound names are generic throughout.

## References

[1] Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-1784. https://pubmed.ncbi.nlm.nih.gov/8637402/
[2] Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998;160(2):389-393. https://pubmed.ncbi.nlm.nih.gov/9679884/
[3] Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. https://pubmed.ncbi.nlm.nih.gov/16412534/
[4] Cardones AR, Grichnik JM, et al. Dermoscopic changes in melanocytic nevi during use of melanotan II. Hautarzt. 2012;63(11):880-884. https://pubmed.ncbi.nlm.nih.gov/23052015/
[5] Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clin Toxicol (Phila). 2012;50(10):1169-1173. https://pubmed.ncbi.nlm.nih.gov/23121206/
[6] Peters B, Hadimeri H, Wahlberg R, Afghahi H. Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN Case Rep. 2020;9(2):159-161. https://pubmed.ncbi.nlm.nih.gov/31953620/
[7] Habbema L, et al. Melanotan-induced priapism: a hard-earned tan. BMJ Case Rep. 2019;12(2):e227644. (See also references 16-18 on priapism and 19 on PRES.) https://pubmed.ncbi.nlm.nih.gov/30796078/
[8] [alpha-Melanocyte-stimulating hormone-induced eruptive nevi.] 2009. https://pubmed.ncbi.nlm.nih.gov/19380666/
[9] Eruptive melanocytic naevi following melanotan injection. 2009. https://pubmed.ncbi.nlm.nih.gov/19575725/
[10] Eruptive naevi and darkening of pre-existing naevi 24 h after a single mono-dose injection of melanotan II. 2014. https://pubmed.ncbi.nlm.nih.gov/24334249/
[11] Hueso-Gabriel L, Mahiques Santos L, Terradez Mas L, Santonja Lopez N. Eruptive dysplastic nevi following melanotan use. Actas Dermosifiliogr. 2012;103(4):329-331. https://pubmed.ncbi.nlm.nih.gov/22425244/
[12] Melanoma associated with the use of melanotan-II. 2014. https://pubmed.ncbi.nlm.nih.gov/24355990/
[13] Melanotan-associated melanoma. 2011. https://pubmed.ncbi.nlm.nih.gov/21564053/
[14] Melanotan-associated melanoma in situ. 2012. https://pubmed.ncbi.nlm.nih.gov/22724573/
[15] Changes of melanocytic lesions induced by Melanotan injections and sun bed use in a teenage patient with FAMMM syndrome. 2012. https://pubmed.ncbi.nlm.nih.gov/23785612/
[16] Devlin JJ, Hung YM, et al. Melanotan II overdose associated with priapism. Clin Toxicol (Phila). 2013;51(4):383. https://pubmed.ncbi.nlm.nih.gov/23537392/
[17] Tonseth KA, et al. Melanotan Tanning Injection: A Rare Cause of Priapism. Sex Med. 2021;9(1):100298. https://pubmed.ncbi.nlm.nih.gov/33460908/
[18] Habbema L, et al. Melanotan-induced priapism: a hard-earned tan. BMJ Case Rep. 2019;12(2):e227644. https://pubmed.ncbi.nlm.nih.gov/30796078/
[19] Melanotan and the posterior reversible encephalopathy syndrome. 2013. https://pubmed.ncbi.nlm.nih.gov/23648958/
[20] Hemodynamic actions and mechanisms of systemically administered alpha-MSH analogs in mice. 2012. https://pubmed.ncbi.nlm.nih.gov/22982611/
[21] Systemic but not central nervous system nitric oxide synthase inhibition exacerbates the hypertensive effects of chronic melanocortin-3/4 receptor activation. 2011. https://pubmed.ncbi.nlm.nih.gov/21263126/
[22] Assessment of the aversive consequences of acute and chronic administration of the melanocortin agonist, MTII. 2003. https://pubmed.ncbi.nlm.nih.gov/12704398/
[23] Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. 2015. https://pubmed.ncbi.nlm.nih.gov/24771717/
[24] LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs. 2021. https://pubmed.ncbi.nlm.nih.gov/33245851/
[25] Eliason NL, Martin L, Low MJ, Sharpe AL. Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for food. Neuropeptides. 2022;96:102289. https://pubmed.ncbi.nlm.nih.gov/36155088/
[26] Operation resistance: A snapshot of falsified antibiotics and biopharmaceutical injectables in Europe. 2016. https://pubmed.ncbi.nlm.nih.gov/26456392/
[27] Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. 2017. https://pubmed.ncbi.nlm.nih.gov/28266027/
[28] Melanotropic peptides: more than just 'Barbie drugs' and 'sun-tan jabs'? 2010. https://pubmed.ncbi.nlm.nih.gov/20545686/
[29] The unregulated use of melanotan-II is of public health interest to Australian dermatologists. 2017. https://pubmed.ncbi.nlm.nih.gov/28905366/
[30] The 'Barbie Drug' - marketing and perceptions of melanotan on social media. 2025. https://pubmed.ncbi.nlm.nih.gov/38808957/
[31] Bonchev A. Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report. Life (Basel). 2026;16(2):265. https://pubmed.ncbi.nlm.nih.gov/41752902/
[32] PT-141: a melanocortin agonist for the treatment of sexual dysfunction. 2003. https://pubmed.ncbi.nlm.nih.gov/12851303/
[33] Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X, Minder EI. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol. 2015;172(6):1601-1612. https://pubmed.ncbi.nlm.nih.gov/25494545/

---

A forward-looking digest of the melanocortin literature — candid about what Melanotan 2 does and the risks it carries, and not a vendor, clinic, or prescription.